BioArctic AB (publ) (LON:0RV2)

London flag London · Delayed Price · Currency is GBP · Price in SEK
318.20
-9.40 (-2.87%)
At close: Feb 11, 2026
Market Cap2.33B +65.1%
Revenue (ttm)151.29M +1,046.5%
Net Income78.93M
EPS0.89
Shares Outn/a
PE Ratio29.53
Forward PE87.55
Dividendn/a
Ex-Dividend Daten/a
Volume3,496
Average Volume18,585
Open326.10
Previous Close327.60
Day's Range315.20 - 323.80
52-Week Range154.60 - 346.20
Beta-0.90
RSI50.13
Earnings DateFeb 18, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 122
Stock Exchange London Stock Exchange
Ticker Symbol 0RV2
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements